Publications Lena Claesson-Welsh

Publications in DiVA 

Publications in PubMed


Selected publications: 

  1. Li X, Padhan N, Sjöström EO, Roche F, Testini C, Honkura N, Sainz-Jaspeado M, Gordon E, Bentley K, Philippides A, Tolmachev T, Dejana E, Stan, RV, Vestweber D, Ballmer-Hofer K, Betsholtz C, Pietras K, Jansson L, Claesson-Welsh L. VEGFR2 pY949 signaling regulates c-Src dynamics and VEGF-induced vascular permeability in cancer and metastatic spread. Nat Commun, 2016, 7:11017.
     
  2. Simons M, Gordon E, Claesson-Welsh L (2016) VEGF receptor signaling and regulation of the vasculature. Nat Rev Mol Cell Biol, in press.
     
  3. Koch S, van Meeteren L, Morin E, Testini C, Weström S, Bjorkelund H, le Jan S, Berger P, Claesson-Welsh L. Neuropilin-1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev Cell 2014, 28(6):633-46.
     
  4. Bentley K, Franco CA; Philippides A, Blanco R, Dierkes M, Gebala V, Stanchi F, Jones M, Aspalter IM, Cagna G, Weström S, Claesson-Welsh L, Vestweber D, Gerhardt H. The role of differential VE-cadherin dynamics during angiogenesis. Nat Cell Biol. 2014, 16(4):309-21.
     
  5. Hayashi M, Majumdar A, Li X, Adler J, Sun Z, Vertuani S, Hellberg C, Mellberg S, Koch S, Dimberg A, Young Koh G, Dejana E, Belting HG, Affolter M, Thurston G, Holmgren L, Vestweber D, Claesson-Welsh L. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat Commun 2013, 4:1672-86.
     
  6. Sun Z, Li X, Massena S, Kutschera S, Padhan N, Gualandi L, Sundvold-Gjerstad V, Gustafsson K, Choy WW, Zang G, Quach M, Jansson L, Phillipson M, Abid MR, Spurkland A, Claesson-Welsh L. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J Exp Med 2012, 209:1363-77.
     
  7. Welsh M, Claesson-Welsh L. VEGF signaling in tumor anigogenesis. J Intern Med. 2013, 273(2):114-27.
     
  8. Rolny C*, Mazzone M*, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito LM, Segura I, Li X, Knelvels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, DeMoi M, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerschin M, Claesson-Welsh L*, Carmeliet P*. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19(1):31-44. *) equal contribution as first/last author.
     
  9. Tugues S, Honjo S, König C, Noguer O, Hedlund M, Botling J, Deschoemaeker S,  Wenes M, Rolny C, Jahnen-Dechent W,  Mazzone  M, Claesson-Welsh L. Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. Cancer Res, 2012, 72(8):1953-63.
     
  10. Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, Söderberg O, Anisimov A, Kholová I, Pytowski B, Baldwin M, Ylä-Herttuala S, Alitalo K, Kreuger J, Claesson-Welsh L. VEGF receptor 2/3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J 2010, 29: 1377-88.